111 related articles for article (PubMed ID: 29360553)
1. Endothelial JAK2
Poisson J; Hilscher MB; Tanguy M; Hammoutene A; Boulanger CM; Villeval JL; Simonetto DA; Valla D; Shah VH; Rautou PE
J Hepatol; 2018 May; 68(5):1086-1087. PubMed ID: 29360553
[No Abstract] [Full Text] [Related]
2. Occurrence of the JAK2 V617F mutation in the Budd-Chiari syndrome.
Colaizzo D; Amitrano L; Tiscia GL; Iannaccone L; Gallone A; Grandone E; Guardascione MA; Margaglione M
Blood Coagul Fibrinolysis; 2008 Jul; 19(5):459-62. PubMed ID: 18600100
[TBL] [Abstract][Full Text] [Related]
3. Laser-capture microdissection and analysis of liver endothelial cells from patients with Budd-Chiari syndrome.
Sozer S; Hoffman R
Methods Mol Biol; 2011; 755():405-15. PubMed ID: 21761323
[TBL] [Abstract][Full Text] [Related]
4. Low frequency of V617F mutation in JAK2 gene in Indian patients with hepatic venous outflow obstruction and extrahepatic portal venous obstruction.
Rai P; Kumar P; Mishra S; Aggarwal R
Indian J Gastroenterol; 2016 Sep; 35(5):366-371. PubMed ID: 27633031
[TBL] [Abstract][Full Text] [Related]
5. Granulocyte whole exome sequencing and endothelial JAK2V617F in patients with JAK2V617F positive Budd-Chiari Syndrome without myeloproliferative neoplasm.
Helman R; Pereira WO; Marti LC; Campregher PV; Puga RD; Hamerschlak N; Chiattone CS; Santos FPS
Br J Haematol; 2018 Feb; 180(3):443-445. PubMed ID: 27650062
[No Abstract] [Full Text] [Related]
6. Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis.
Karaköse S; Oruç N; Zengin M; Akarca US; Ersöz G
Turk J Gastroenterol; 2015 Jan; 26(1):42-8. PubMed ID: 25698270
[TBL] [Abstract][Full Text] [Related]
7. [Budd-Chiari syndrome and splanchnic vein thrombosis: masked myeloproliferative neoplasms and JAK2V617F].
Fama A; Rago A; Gioiosa F; Marzano C; Latagliata R; Mammì C; Laganà C; D'Elia GM; Bizzoni L; Trasarti S; Ferretti A; Breccia M; Riggio O; Tafuri A
Clin Ter; 2010; 161(2):169-71. PubMed ID: 20499034
[TBL] [Abstract][Full Text] [Related]
8. JAK2 mutations across a spectrum of venous thrombosis cases.
Shetty S; Kulkarni B; Pai N; Mukundan P; Kasatkar P; Ghosh K
Am J Clin Pathol; 2010 Jul; 134(1):82-5. PubMed ID: 20551270
[TBL] [Abstract][Full Text] [Related]
9. JAK2 V617F Mutation Testing in Patients Presenting With Hepatic and Portal Vein Thrombosis.
Foucar CE; Stein BL
JAMA; 2017 Jun; 317(21):2228-2229. PubMed ID: 28586872
[No Abstract] [Full Text] [Related]
10. Hypereosinophilia, JAK2V617F, and Budd-Chiari syndrome: who is responsible for what?
Mishchenko E; Tadmor T; Schiff E; Attias D; Polliack A
Am J Hematol; 2011 Feb; 86(2):223-4. PubMed ID: 21264914
[TBL] [Abstract][Full Text] [Related]
11. JAK2 mutation: The best diagnostic tool for myeloproliferative disease in splanchnic vein thrombosis?
Janssen HL; Leebeek FW
Hepatology; 2006 Dec; 44(6):1391-3. PubMed ID: 17133464
[No Abstract] [Full Text] [Related]
12. The JAK2 46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis.
Smalberg JH; Koehler E; Darwish Murad S; Plessier A; Seijo S; Trebicka J; Primignani M; de Maat MP; Garcia-Pagan JC; Valla DC; Janssen HL; Leebeek FW;
Blood; 2011 Apr; 117(15):3968-73. PubMed ID: 21364191
[TBL] [Abstract][Full Text] [Related]
13. Low burden of a JAK2-V617F mutated clone in monoclonal haematopoiesis in a Japanese woman with Budd-Chiari syndrome.
Toyama K; Karasawa M; Yamane A; Koiso H; Yokohama A; Uchiumi H; Saitoh T; Handa H; Sato K; Takagi H; Miyawaki S; Murakami H; Nojima Y; Tsukamoto N
Int J Hematol; 2009 May; 89(4):517-522. PubMed ID: 19308656
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of the JAK2 V617F mutation associated with splanchnic vein thrombosis. A 10-year retrospective study.
Tondeur S; Boutruche S; Biron-Andréani C; Schved JF
Thromb Haemost; 2009 Apr; 101(4):787-9. PubMed ID: 19350131
[No Abstract] [Full Text] [Related]
15. Prevalence of JAK29V617F) mutation in intra-abdominal venous thrombosis.
Deepak A; Punamiya S; Patel N; Parekh S; Mehta S; Shah N
Trop Gastroenterol; 2011; 32(4):279-84. PubMed ID: 22696908
[TBL] [Abstract][Full Text] [Related]
16. Absence of the JAK2 exon 12 mutations in patients with splanchnic venous thrombosis and without overt myeloproliferative neoplasms.
Fiorini A; Chiusolo P; Rossi E; Za T; De Ritis DG; Ciminello A; Leone G; De Stefano V
Am J Hematol; 2009 Feb; 84(2):126-7. PubMed ID: 19105231
[No Abstract] [Full Text] [Related]
17. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome.
Sozer S; Fiel MI; Schiano T; Xu M; Mascarenhas J; Hoffman R
Blood; 2009 May; 113(21):5246-9. PubMed ID: 19293426
[TBL] [Abstract][Full Text] [Related]
18. Budd Chiari syndrome and V617F/JAK 2 mutation linked with the myeloproliferative disorders.
Smira G; Gheorghe L; Iacob S; Coriu D; Gheorghe C
J Gastrointestin Liver Dis; 2010 Mar; 19(1):108-9. PubMed ID: 20361090
[No Abstract] [Full Text] [Related]
19. MPL and JAK2 exon 12 mutations in patients with the Budd-Chiari syndrome or extrahepatic portal vein obstruction.
Bergamaschi GM; Primignani M; Barosi G; Fabris FM; Villani L; Reati R; Dell'era A; Mannucci PM
Blood; 2008 Apr; 111(8):4418. PubMed ID: 18398061
[No Abstract] [Full Text] [Related]
20. Absence of JAK2-V617F in paroxysmal nocturnal haemoglobinuria-associated thrombosis.
Fouassier M; Girodon F; Cleyrat C; Robillard N; Garand R; Hermouet S
Thromb Haemost; 2009 Jul; 102(1):180-2. PubMed ID: 19572087
[No Abstract] [Full Text] [Related]
[Next] [New Search]
